The Long‐Term Management of Obesity in General Practice

Jt, Silverstone; Solomon, Thomas P. J.

doi:10.1111/j.1742-1241.1965.tb03144.x

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1965

2001

Publication Types

Select...

Article7

Relationship

Self Cite0

Independent7

Authors

Journals

Cited by 40 publications

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is true for each month of the trial including the first. Therefore initial enthusiasm plus Ro 4-5282 is more effective than initial enthusiasm alone -a finding in accordance with previous studies using other anorectic preparations (Silverstone and Solomon. 1965).…”

Section: Discussionsupporting

confidence: 91%

Controlled Trial of a New Anorectic Drug in the treatment of Obesity

Solomon²,

Ross³

et al. 1967

Int J Clinical Practice

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 91%

Controlled Trial of a New Anorectic Drug in the treatment of Obesity

Solomon²,

Ross³

et al. 1967

Int J Clinical Practice

View full text Add to dashboard Cite

“…Intermittent treatment with anorectic agents may avoid the development of tolerance and in this trial a greater loss of weight was achieved during the second period of treatment than during the first. A similar pattern of weight loss has also been demonstrated in comparable studies using intermittent dosages of other anorectic agents (Silverstone and Solomon, 1965; Silverstone and Buckle, 1966).…”

Section: Introductionsupporting

confidence: 72%

Weight control in Obese Diabetics: A comparative trial of Filon and phenmetrazine

Buckle

Silverstone

1966

Int J Clinical Practice

View full text Add to dashboard Cite

Long-term Pharmacotherapy of Obesity 2000

Glazer¹

2001

Arch Intern Med

152

101

View full text Add to dashboard Cite

To clarify the efficacy of antiobesity drugs, this article reviews all long-term (> or =36 weeks), placebo-controlled trials of obesity pharmacotherapy published since 1960. Since fears of anorexiant-induced heart valve damage preclude many physicians and patients from even considering antiobesity drugs, this area is also reviewed in-depth. Electronic database and manual bibliography search was used to identify all relevant publications. While existing studies are too few and heterogeneous to warrant meta-analysis, their review does provide evidence highly relevant to the safety and efficacy of available anorexiants. Weight loss attributable to obesity pharmacotherapy (ie, in excess of placebo) in trials lasting 36 to 52 weeks was 8.1% or 7.9 kg for those receiving phentermine resin, 5.0 % or 4.3 kg for those receiving sibutramine hydrochloride, 3.4% or 3.4 kg for those receiving orlistat, and -1.5% or -1.5 kg for those receiving diethylpropion hydrochloride. Physiologic, pathologic, and epidemiological studies strongly support that anorexiant-induced valvulopathy is attributable to specific serotonergic properties of the fenfluramines that are not present with available weight loss drugs.

show abstract

The Long‐Term Management of Obesity in General Practice

Cited by 40 publications

References 2 publications

Controlled Trial of a New Anorectic Drug in the treatment of Obesity

Controlled Trial of a New Anorectic Drug in the treatment of Obesity

Weight control in Obese Diabetics: A comparative trial of Filon and phenmetrazine

Long-term Pharmacotherapy of Obesity 2000

Contact Info

Product

Resources

About